Mode
Text Size
Log in / Sign up
N/A Completed N=109 Treatment

Evaluation of Exufiber Ag+ and Other Gelling Fibre Dressings

Wounds and Injuries
Source: ClinicalTrials.gov NCT03249909 ↗
Enrolled (actual)
109
Serious AEs
7.3%
Results posted
Sep 2020
Primary outcomePrimary: Change in Exudate Status From Baseline to Last Visit — 27; 3; 7; 40 Participants — p=0.0019

Summary

Investigate impact of gelling fiber dressings on handling exudate in medium to high exuding wounds

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Exudate Status From Baseline to Last Visit
27; 3; 7; 40; 6; 8 0.0019 sig
SECONDARY
4-Week Wound Status
2; 1; 1; 5; 3; 0
SECONDARY
Wound Area Reduction (mm^2)
-388.4; -296.3; -274.7
SECONDARY
Frequency of Dressing Changes Between Visits
1.36; 0.511; 3.56
SECONDARY
Tissue Type of Wound Bed
2.13; 1.54; 2.5; -6.48; -2.69; -0.833
SECONDARY
Status of the Wound and Peri-wound Skin From Baseline to Last Visit: Malodour
3; 0; 0; 45; 8; 9
SECONDARY
Status of the Wound and Peri-wound Skin From Baseline to Last Visit: Redness/Irritation
8; 0; 1; 53; 13; 9
SECONDARY
Status of the Wound and Peri-wound Skin From Baseline to Last Visit: Maceration
16; 0; 5; 39; 13; 7
SECONDARY
Handling and Technical Performance of the Dressing
57.8; 100.0; 66.7; 56.4; 85.7; 63.6
SECONDARY
Comfort, Conformability, and Acceptability of the Dressings by Subject
44.3; 57.1; 66.7; 41.0; 64.3; 66.7

Eligibility Criteria

Inclusion Criteria

  • Signed Informed Consent Form
  • Both gender ≥ 18 years old
  • From Medium to High exuding wound

Exclusion Criteria

  • Known allergy or hypersensitivity to any of the treatment dressings
  • Pregnant or lactating females
  • Subjects with a target wound that is ≤1 cm2
  • Subjects with a target wound that is a full thickness burn
  • Subjects with a target wound that is a full thickness pressure ulcer
  • Subjects with known immunodeficiency
  • Subject taking systemic antibiotics for wound infection
  • Subject were the target wound is located on an infected limb interfered by minimal blood flow in the opinion of the investigator
  • Subject with a target wound with unexplored enteric fistula
  • Subjects who in the opinion of the investigator, will have problems following the protocol
  • Subjects needing treatment with oxidizing agents such as hypochlorite solutions or hydrogen peroxide
  • Previously enrolled in the present investigation
  • Inclusion in other ongoing investigations at present that would preclude the subject from participating in this investigation as judged by the investigator
  • Involvement in the planning and conduct of the clinical investigation
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03249909). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search